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Brigitta Nagy a,b, Botond Szilágyi c,*, András Domokos a, Blanka Vészi a, Kornélia Tacsi a, 
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A B S T R A C T   
The integration of continuous unit operations imposes a challenge on the pharmaceutical companies aspiring to 
achieve plant-wide continuous manufacturing due to the additional complexity of the dynamic interactions, 
process control and quality assurance. To overcome this challenge, flowsheet modeling emerged as a viable tool 
to gain deeper process knowledge. In this work, the dynamic model of the integrated continuous manufacturing 
of acetylsalicylic acid (ASA) was formed based on real continuous unit operations. Furthermore, the surrogate 
model of the in vitro dissolution test of ASA capsules was integrated into the flowsheet model the first time to 
analyze the integrated manufacturing in light of the dissolution specifications of an immediate-release formu-
lation. Systematic optimization studies were performed on the integrated process and on the continuous unit 
operations step-by-step, which clearly revealed the impact of the plant-wide dynamic modeling, as the integrated 
approach resulted in the threefold increase in the overall productivity and the parallel decrease in the required 
reactant excess. Sensitivity analyses of the operating conditions and the kinetic parameters were also performed. 
The crystallization temperature emerged as one of the most critical parameters, which variation could even result 
in the failure of the dissolution specification. Moreover, by calculating the time-varying sensitivity indices, the 
dynamics of the error propagation could be studied. These results could facilitate the integration of existing 
continuous units, the development of the control strategy, and encourage the implementation of dissolution 
surrogate models into process flowsheet simulations.   
1. Introduction 
In the last decade, the pharmaceutical industry has started to un-
dergo a vast transformation, which aims the implementation of flexible 
and efficient manufacturing as opposed to the traditional, conservative 
approach of fixed process conditions. This is promoted by several ad-
vances in parallel. From the technology point of view, innovations in 
continuous manufacturing equipment are rapidly emerging, providing 
options for consistent and economical production [1], and the regula-
tory agencies support the concept by providing guidelines [2] and ini-
tiatives, such the Quality-by-Design (QbD) [3] and Process Analytical 
Technology (PAT) [4]. These principles focus on the knowledge- and 
risk-based operation of the manufacturing process by the thorough 
mapping of the underlying critical material attributes (CMAs) and pro-
cess parameters (CPPs) and their effect on the target product profile. The 
most important tools for this are real-time, in-line measurements as well 
as various statistical and mechanistic modeling methodologies [5,6]. 
Due to the additional complexity of continuous manufacturing lines, 
the importance of the systematic model-based design of the product and 
processes has increased. Mechanistic dynamic flowsheet models have 
been identified as excellent tools for representing the process knowledge 
and dynamically analyze the input–output relationship [7]. Together 
with widely used analysis tools, e.g., sensitivity analysis [8], this con-
tributes to the identification of the excessive variation and risk of error 
propagation, the optimization of the process, and the development of 
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control strategies [7,9]. Furthermore, when continuous communication 
is enabled between the model and the real process, a digital twin is 
created, which can be further used e.g., for model-predictive control 
[10]. 
The concept of flowsheet modeling of continuous manufacturing has 
been already utilized by several authors for both the upstream (active 
pharmaceutical ingredient (API) manufacturing) and downstream (final 
product manufacturing) process steps, and software packages are also 
available to facilitate their development, such as gPROMS by Process 
Systems Enterprise [11]. As for the upstream part, a dynamic flowsheet 
model of ibuprofen synthesis and crystallization was developed and the 
uncertainty of the process was systematically studied [12]. Diab et al. 
studied the flowsheet model of the synthesis and crystallization of 
rufinamide [13] and nevirapine [14] in the view of techno-economic 
considerations, such as minimizing the production costs. Most 
recently, Icten et al. published a three-part series of papers [15–17] 
dealing with the development of a virtual plant for continuous 
manufacturing of carfilzomib intermediate, intending to gain a 
mechanistic understanding of the synthesis, crystallization and filtration 
unit operations, and to use the modeling framework to identify the CPPs 
that impact the conversion in their integrated system. 
From the perspective of the downstream process modeling of solid 
products, mainly the continuous feeding, blending and tablet compres-
sion steps are integrated [18–20], but there are also examples for 
incorporating dry [21] and wet granulation [22] steps. Wang et al. [20] 
utilized the developed flowsheet model for the optimization of the 
process to minimize the total cost of the manufacturing. In most of the 
studies [18–20,22] sensitivity analysis was performed using the unit 
operation parameters (e.g., residence times, flow rates) and final prop-
erties of the product, e.g., tablet hardness and weight, API concentration 
as examined response variables. However, only a few modeling studies 
incorporated both the upstream and downstream manufacturing steps. 
Sen et al. [23,24] used such a model for analyzing the mixing properties 
in connection with the crystallization, filtration and drying processes, 
while in another study [25] the simulations were used to improve the 
overall productivity and quality of the manufacturing. Moreover, no 
List of notations 
Ai Pre-exponential factor of the ith reaction 
AS Antisolvent- solvent volume ratio 
B Nucleation rate [# m-3s− 1] 
b Nucleation rate exponent [-] 
c Concentration in solution [M] (in synthesis); [kgm− 3] (in 
crystallization) 
cd Mass fraction of API in the dissolution medium [-] 
c*c Equilibrium solubility in the crystallization [kgm
− 3] 
c*d Equilibrium solubility in the dissolution medium [g ASA/ g 
solution] 
ci Impurity concentration [M] (in the synthesis); [kgm− 3] (in 
crystallization) 
cin Inlet concentration of solution [kgm− 3] 
cnorm Normalized concentration in solution [M] (in synthesis); 
[kgm− 3] (in crystallization) 
cs Solid concentration [kgm− 3] 
D Dissolution rate [ms− 1] 
DR Dissolved ratio [%] 
d Dissolution rate exponent [-] 
E(t) Residence time distribution 
EE Elementary effect 
Ea,g Growth activation energy [Jmol− 1] 
Ea,i Activation energy of the ith reaction [Jmol− 1] 
F Flow rate [m3s− 1] 
G Growth rate [ms− 1] 
KL Langmuir constant [kgm− 3] 
kb Nucleation rate coefficient [# m− 3 s− 1] 
kd Dissolution rate coefficient [m s− 1] 
kg Growth rate coefficient [ms− 1] 
ki Reaction rate constant of the ith reaction [Jmol− 1] 
kv Volume shape factor [-] 
L Linear size of crystals [m] 
Ln Nuclei size [m] 
mc Sample mass in the dissolution test [kg] 
N Reactor number [#] 
n Population density [# m− 4] 
nin Initial population density [#m− 43] 
nMSE Normalized mean square error [M2] 
nMSEnorm Normalized mean square error calculated for normalized 
concentrations [M2] 
O(D) Objective function 
P Purity [%] 
pi Coefficients of size-dependent dissolution [-] 
R Universal gas constant, 8.314 JK-1mol− 1 
ri Rate law equation of the the ith reaction 
T Temperature [◦C] 
t Time [s] 
V Volume [m3] 
v Antisolvent volume fraction in feed [-] 
vc Crystal volume fraction in the dissolution medium [-] 
X Conversion [%] 
Greek Letters 
α Effectiveness factor [-] 
δ Dirac-delta function 
μ2 2nd moment of the CSD [m
2m− 3] 
μ3 3rd moment of the CSD [m
3m− 3] 
μM Mean of elementary effects 
ρc Crystal density [kgm
− 3] 
ρd Density of the dissolution medium [kgm− 3] 
σ Relative supersaturation [-] 
σ2 Standard deviation of the reactor residence time 
distribution [s] 
σ2M Standard deviation of elementary effects 





j Sample point 
m Measured data 
q Quenching 
X Component in the reaction mixture 
0 Initial state  
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studies were found where the final quality of the formulation was 
assessed from the point of dissolution properties, although the in vitro 
dissolution is one of the most important and routinely analyzed quality 
attributes of solid pharmaceutical products [26]. Hence, the mathe-
matical description could significantly contribute to the product and 
process development and release testing. This could be achieved either 
by first principles-based or black-box modeling approaches [27]. 
This paper presents the dynamic, integrated flowsheet model 
development for the continuous manufacturing of acetylsalicylic acid 
(ASA), involving a two-step flow synthesis and crystallization. The 
model was built to simulate the real continuous processes developed 
formerly by the authors of this paper [28,29]. In these former works, the 
unit operations were studied separately to analyze the effect of the 
different process parameters. As for the synthesis, the reaction mixture 
composition, processing temperature and residence times were opti-
mized experimentally for maximal conversion and purity and minimal 
processing time [28], but the main priority was to obtain a reaction 
mixture which is directly connectable with electrospinning. The pro-
cessing of this flow reaction mixture in continuous combined cooling 
and antisolvent crystallization process was also developed, where the 
effect of the crystallization temperature, the solvent system composition 
and residence time was studied on the crystal size distribution (CSD), 
yield and purity [29]. However, the integration of the synthesis and 
crystallization steps has not been achieved, yet. Therefore, to facilitate 
the integration of the existing unit operations, this work aimed the 
development of a dynamic flowsheet model to gain process under-
standing on the operation of the continuous, integrated process. This 
study is also the extension of a previous publication [30], where the 
dynamic model of the continuous crystallization was presented, but it 
dealt mainly with the integrated simulation of the continuous crystal-
lization and filtration, e.g., the effect on the CSD and solid concentration 
was analyzed on the continuous filtration. Consequently, together with 
the present work, the dynamic model of the fully continuous, integrated 
upstream process is achieved. The true potential of the integrated 
flowsheet model is demonstrated via optimization studies and sensitivity 
analysis. Furthermore, the surrogate in vitro dissolution model of cap-
sules containing the obtained ASA powder is developed and integrated 
into the flowsheet model. Such a model can be useful when the disso-
lution of the capsules is affected solely by the API characteristics. 
Moreover, it could contribute to a better understanding of the CSD as 
CMA and the corresponding optimization and risk analysis of the API 
manufacturing process during the early stage of the drug development 
even in the case of more complex formulations. To the best of the au-
thors’ knowledge, this is the first time when flowsheet modeling is uti-
lized for studying the dissolution properties of the final product of 
continuous pharmaceutical manufacturing. 
2. Materials and methods 
2.1. Experimental procedures 
The mathematical model of the integrated continuous synthesis- 
crystallization process and the in vitro dissolution properties was 
developed based on real, laboratory-scale continuous processes and 
experimental data. The synthesis and crystallization procedures have 
been originally published in [28] and [29] and the experiments used for 
the parameter estimation and validation of the synthesis and crystalli-
zation steps came from these works. Although the experiments were 
originally conducted for the experimental development of the technol-
ogies and not for the purpose of the mathematical model fitting, they 
were found to be suitable for the parameter estimations as the viable 
ranges of the operating conditions were explored in different combina-
tions. The experiments were divided into calibration and validation sets. 
A quasi-random division was aimed: the ratio depended on the total 
number of the available experiments, and the validation experiments 
were selected randomly, but it was also accounted that the validation set 
should cover the whole range of the settings. 
2.1.1. Synthesis 
The modeling of the continuous synthesis of ASA was based on the 
experimental work of Balogh et al. [28]. The two-step flow synthesis 
consisted of acetylation and a subsequent quenching step. For acetyla-
tion, a 1 mol L-1 solution of salicylic acid (SA) was prepared in ethyl 
acetate (EtOAc), also containing phosphoric acid (H3PO4) as a catalyst in 
0.1 mol equivalent relative to SA. SA was acetylated continuously with 
excess acetic anhydride (AA). In the subsequent quenching step ethanol 
(EtOH) was added to the reaction mixture of the first step, to remove the 
excess AA and the quenchable impurities. The reactions were carried out 
in 8.77 and 1.83 m long tube flow reactors for the acetylation and 
quenching step, respectively with an inner diameter of 0.787 mm. 4 bar 
was used to maintain constant fluid flow conditions. 
Acetylation experiments were conducted first in batch mode to 
analyze the effect of the AA excess (AAeq, mole equivalent relative to SA) 
and the acetylation temperature (Ta), then in continuous mode to adjust 
the temperature and the residence time (τa), while AAeq was fixed to 5, 
based on the outcomes of the batch experiments. At the quenching step, 
the EtOH ratio (EtOHeq, mole equivalent relative to the initial SA), 
residence time (τq), and quenching temperature (Tq), were analyzed in 
continuous mode, whereas AAeq, Ta and τa were fixed to 5, 55 ◦C and 
180 min, respectively. The composition of the reaction mixture was 
measured by HPLC [28] every 10–20 min in the case of the batch 
acetylation and in the steady state of the continuous runs. Tables 1 and 2 
summarize the acetylation and quenching experimental settings utilized 
in this study to estimate the kinetic parameters of the mathematical 
model. For further details on the experimental setup, the reader is 
referred to [28]. 
2.1.2. Crystallization 
A combined cooling and antisolvent (CCAS) continuous crystalliza-
tion method has been developed to crystallize the ASA from the reaction 
mixture obtained in the flow synthesis [29]. The crystallization experi-
ments were performed in mixed-suspension, mixed-product-removal 
(MSMPR) continuous crystallizer operated at 235 mL constant volume 
and using heptane as antisolvent. Experiments were performed with 0.8 
antisolvent volume fraction (v) and varying flow rates (Fc), temperatures 
(Tc) and residence times (τc) in the ranges of 5–20 mL min− 1, 2–25 ◦C 
and 10–50 min, respectively. Details on the crystallization experimental 
setup, procedure, the experiments for the kinetic parameter estimation 
and the parameter estimation can be found in our previous publications 
[29,30]. 
2.1.3. In vitro dissolution testing 
To investigate the effect of the crystal size distribution (CSD) on the 
in vitro dissolution of the final product (e.g., capsule), samples for 
dissolution testing were prepared by sieving ASA powder using 63, 100, 
Table 1 
Experimental setting used for the kinetic parameter estimation and validation of 
the acetylation step.  
Experiment 
No. 
Ta[◦C]  AAeq[-]  Experiment 
No. 
Ta[◦C]  τa[min]  
Abatch 1 20 1.5 Acont. 1 50 60 
Abatch 2 20 5 Acont. 2 50 120 
Abatch 3 50 1.5 Acont. 3 70 120 
Abatch 4 50 10 Acont. 4 60 90 
Abatch 5 77 5 Acont. 5 65 180 
Abatch 6 77 10 Acont. 6 45 120 
Abatch Val 1 20 10 Acont. 7 65 120 
Abatch Val 2 50 5 Acont. 8 55 150 
Abatch Val 3 77 1.5 Acont. 9 55 180    
Acont. Val 1 70 60    
Acont. Val 2 60 90    
Acont. Val 3 45 180  
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150, 200, 300 and 500 μm sieve openings as well as by combining equal 
weights of sieve fractions (Table 3). Additionally, two continuously 
crystallized crystal products (MSMPR 1 and 2) were also used for vali-
dation. The CSD of each sample was collected by a Parsum IPP 70-s 
inline particle sizing probe (Malvern Panalytical Ltd., UK) in batch 
mode. The samples were dispersed into the instrument for estimating the 
cord length of the crystals, which were used to construct the number- 
based CSDs in the 50–2000 μm size range with a logarithmic grid with 
50 bins. 
Then dissolution tests of 100 mg powders were carried out in powder 
form as well as in some cases (see Table 3) filling them into capsules. The 
tests were performed in a Hanson SR8-Plus dissolution tester (Hanson 
Research, USA) using the paddle method (United States Pharmacopoeia 
II). In the case of the capsules, a spiral capsule sinker was used to prevent 
the floating of the capsules. 900 mL of 0.1 N HCl solution was used as 
dissolution medium, stirred at 100 rpm and kept at constant tempera-
ture of 37 ± 0.5 ◦C, which ensured sink condition. An on-line coupled 
Agilent 8453 UV–VIS spectrophotometer (Hewlett-Packard, USA) was 
used to measure the concentration of dissolved ASA for 2 h by sampling 
every 2.5 min until 20 min, followed by sampling in every 10 min until 
120 min. 
Due to the possible degradation of the dissolved ASA to SA during the 
dissolution process (in preliminary tests ~ 2% of the ASA degraded in 1 
h), the SA and ASA needed to be quantified simultaneously. Although 
this would be possible by an HPLC method, a Partial Least Squares (PLS) 
calibration model was developed for the evaluation of the UV–VIS 
spectra based on HPLC data to avoid the lengthy and labor-intensive 
HPLC measurement. The degradation was observed in the UV–VIS 
spectra by the gradual shift of the 229 nm ASA band, the appearance of a 
weak and broad SA band in the 270–320 nm region, which overlapped 
with a weak signal of the ASA in the 260–280 nm region. Therefore, the 
PLS model was developed for the 278–320 nm region of the mean- 
centered UV absorbance spectra with 2 latent variables. The calibra-
tion samples contained different amounts of ASA and SA in the 80–120 
and 0–30 mg L-1 concentration ranges, respectively, which composition 
was determined by an HPLC method [28]. The R2 of the calibration and 
cross-validation was both 0.98, while a root mean square error of cali-
bration and cross-validation of 4.78 and 5.46 mg L-1 was obtained, 
respectively. 
2.2. Mathematical modeling and kinetic parameter identification 
The model-equations were solved in MATLAB R2020a (Math-
Works®, USA), the integrated flowsheet simulation was implemented in 
Simulink 10.1 (MathWorks®, USA). 
2.2.1. Flow synthesis 
Based on the experimental observations [28], the reaction network 
of the acetylation step was constructed by accounting not only the 
conversion of SA to ASA (Eq. (1.a)) but also the formation of two im-
purities, namely acetylsalicylic ethanoic anhydride (Impurity A) and 
acetylsalicylic anhydride (Impurity B) [28] (Eqs. (1.b) -(1.d)). 
SA+AA →
k1 ASA+HA (1.a)  
ASA+AA →
k2 A+HA (1.b)  
A + ASA ⇌
k3 ,k3r
B + HA (1.c)  
SA+ 2AA →
k4 A+ 2HA (1.d) 
where HA, A and B denote acetic acid, Impurity A and Impurity B, 
respectively. 
At the subsequent quenching step, it was observed, that besides the 
decomposition of AA using EtOH, possible reactions of Impurity A and 
ASA also have to be considered (Eqs. (2.a) -(2.c)): 
A+EtOH →
k5 ASA+EtOAc (2.a)  
AA+EtOH →
k6 EtOAc+HA (2.b)  
ASA + EtOH ⇌
k7 ,k7r
SA + EtOAc (2.c) 





where Ai is the pre-exponential factor, Ea,i [J mol− 1] is the activation 
energy, T [◦C] is the reaction temperature and R is the gas constant 
(8.314 J K− 1 mol− 1) of the ith reaction. 





Experimental setting used for the kinetic parameter estimation and validation of the quenching step.  
Experiment No. Tq[◦C]  τq[min]  EtOHeq[-]  Experiment No. Tq[◦C]  τq[min]  EtOHeq[-]  
Q 1 80 15 3 Q 11 80 21 3 
Q 2 80 5 6 Q 12 90 26 3 
Q 3 60 15 6 Q 13 100 31 3 
Q 4 60 15 3 Q Val 1 80 15 6 
Q 5 60 5 6 Q Val 2 80 5 3 
Q 6 70 10 4.5 Q Val 3 60 5 3 
Q 7 85 22 3 Q Val 4 70 10 4.5 
Q 8 95 29.5 3 Q Val 5 90 26 3 
Q 9 100 33 3 Q Val 6 100 21 3 
Q 10 80 31 3      
Table 3 
Calibration and validation samples of the in vitro dissolution studies. The sam-
ples that were measured both in powder and capsule form are indicated in bold.  
Calibration samples Validation samples 
Sample 
name 
Sieve fraction [μm] Sample 
name 
Sieve fraction [μm] 
63 63–100 63 þ 300 (63–100) þ(300–500) 








200 200–300 0 + 63 (<63)+(63–100) 
300 300–500 100 100–150 
500 >500 150 150–200 
100 þ 300 (100–150) 
þ(300–500) 
200 200–300 
150 þ 200 (150–200) 
þ(200–300) 
300 300–500 




MSMPR 1 – 
63 þ 500 (63–100) þ(>500) MSMPR 2 –  
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where cX denotes the concentration of the reaction component taking 
part in the given reaction. The rate law equations for each reaction are 
detailed in the Appendix. 
The continuous flow synthesis can be described using an axial 
dispersion tubular reactor model, which consists of a set of partial dif-
ferential equations (PDEs) [31]: 
∂cX




∂x2 + r (5) 
where x corresponds to the spatial coordinate along the flow reactor, 
t is the time, cX is the concentration of the reaction component X, Dm is 
dispersion coefficient and r represents a set of rate law equations. The 
initial conditions for the PDEs correspond to the initial concentrations 
along the length of the reactor. At the reactor inlet and outlet, the 
Danckwerts boundary conditions apply [31], where the inlet boundary 
conditions are 








= 0 (6) 








= 0 (7) 
Although Eqs. (5)-(7) enables the concentration calculation through 
time and the spatial coordinate of the reactor, it requires the solution of 
PDEs, which cannot be directly implemented in the integrated, dynamic 
flowsheet simulation in Simulink. To overcome this problem, a tank-in- 
series (TIS) approximation of the axial dispersion model was used in this 
study, approximating the tubular flow reactor as a cascade of N equal- 
sized continuous stirred-tank reactors (CSTRs). In this case, assuming 
constant working volume, an ordinary differential equation (ODE) sys-
tem was formed for each CSTR to describe the changes in the concen-
trations of the reaction components for both the acetylation (Eq.8) and 














In Eqs. (8)-(9), the subscripts a and q are referring to the acetylation 
and quenching step, respectively, τ denotes the mean residence time [s] 
in the reactor, which is infinite during the modeling of the batch re-




where V is the reactor volume [m3] and F is the flow rate [m3 s− 1]. 
For Eqs. (8)-(9), the initial conditions ca,X(0) = ca,X,0 and cq,X(0) = cq,X,0 
apply, where the initial ca,X,0 concentration was calculated based on the 
concentration of the SA solution and the applied AAeq, while cq,X,0 was 
calculated from the outlet acetylation concentrations and EtOHeq. 
The volume of the CSTRs in the cascade (Vi) is calculated by dividing 





The number of the necessary reactors was derived based on the 
reactor residence time distribution (RTD). The reactors were assumed to 
operate as laminar flow reactors (the Reynolds numbers ranged from 0.5 
to 5 for the reactor settings summarized in Table 1-2), which residence 














where the mean residence time (τ) and the standard deviation (σ2) of 








(t − τ)2E(t)dt (14) 




N was calculated for the τa and τq values detailed in Tables 1 and 2. 
The calculations resulted in N values between 3.920 and 3.933, with a 
slight rising trend as τ increased. Therefore, 4 CSTRs were used in 
cascade for the simulation of both the acetylation and quenching steps in 
the continuous reactors. The compartmental model assumes that there is 
only convective transfer between the CSTRs of the cascade without 
diffusive transfer, which is a basic assumption of the traditional tank-in- 
series model, as detailed in [31]. 
The reaction kinetic parameters (Ai and Ea,i) were estimated using 
the batch and the continuous experimental data for the acetylation step 
in different combinations and the flow reactions for the quenching step 
(see Tables 1 and 2). The calculations were performed using the 
Covariance Matrix Adaptation Evolution Strategy (CMA-ES), an accel-
erated global optimization algorithm that improves the chance of 
finding the global optimum [32]. The objective functions were formed 
depending on whether the batch or the continuous experimental data 
was used for parameter estimation. In the case of the batch data, the 
normalized mean square errors (nMSE) were calculated between the 
calculated and measured concentrations for SA, ASA, Impurity A and 
Impurity B. Normalization of the error components was performed by 
the difference between the maximum and minimum of the concentration 
for each component, so that each error component had equal weight in 















where cm,j and cj are the measured and calculated concentrations in 
the jth sample point, K is to the total number of the sample points and X 
denotes component SA, ASA, Impurity A and Impurity B. For the 
continuous experiments, only steady state concentrations were avail-
able, from which the nMSEs were further calculated by using normalized 
concentration values (cnorm,m,j, cnorm,j), where the normalization was done 
to unit sum (Eq. (17)). This could be reasoned by the fact, that for the 
simulation of the continuous integrated processes, it is more important 
to capture the concentrations relative to each other caused by the 
varying operation parameters, rather than the absolute concentrations. 
In this way, information on the absolute concentration is eliminated, but 
including the nMSEnorm,X terms into the objective function (Eq. (21)) 
guided the parameter estimation to retain the concentrations relative to 
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Denoting the vector of the considered decision variables by D, the 
objective functions of the parameter estimation (O) from batch and 
continuous data took the form: 
O(D)batch = nMSESA + nMSEASA + nMSEA + nMSEB (20)  
O(D)cont = nMSESA + nMSEASA + nMSEA + nMSEB + w⋅
(
nMSEnorm,SA
+ nMSEnorm,ASA + nMSEnorm,A + nMSEnorm,B
)
(21) 
In Eq. (20)-(21), the decision variable D comprises the Ai and Ea,i 
parameters of the acetylation and quenching reactions (see Table 6 and 
7). In Eq. (21), the weight factor (w) was set to 2 based on preliminary 
optimizations such as both the absolute concentration values as well as 
their relative changes through the experiments were satisfactory. When 
both the batch and continuous data were used for parameter estimation, 
the objective function was obtained by summarizing O(D)batch and 
O(D)cont . The error of fit to the validation experiments was calculated the 
same way, with the exception that for the continuous samples w = 0 
were used for a better comparison of the batch and continuous results. In 
addition to the estimation of nominal parameters, the effects of 
parameter uncertainties were analyzed on the simulated outputs. This 
was performed by executing a sufficiently large number of simulations 
(1000) with kinetic parameter combinations, obtained by Monte-Carlo 
sampling from the confidence hyper ellipsoid defined by the covari-
ance matrix of the nominal parameters [33]. 
2.2.2. Continuous crystallization 
The continuous crystallization of ASA from the reaction mixture was 
simulated using a one-dimensional population balance model (PBM), 
developed formerly by the authors of this paper [30]. It was assumed 
that the kinetics does not depend on the solvent composition. In the 
previous study [30], various model structures were tested, accounting 
secondary nucleation, size-independent growth and size-independent 
agglomeration and it was observed that neglecting agglomeration did 
not result in considerable performance degradation: the model with 
agglomeration resulted in 0.770 fitting error as opposed to the 0.772 
error obtained without agglomeration, and no visible difference could 
be observed in the fit of the validation CSDs. For more details see [30]. 
Since the simulation of agglomeration has the highest computational 
burden amongst the considered mechanisms, a secondary nucleation 
and growth PBM was applied. In this way, the PB equation (PBE) took 
the form of Eq. (22), where the first term on the left-hand side defines 
Table 5 
Constants of the in vitro dissolution model.  
Variable Unit Value 
mc  mg 100 
Vd  mL 900 
ρd  kg m− 3 1000 
td,max  min 120 
Td  ◦C 37 
c*d  [g ASA/g solution] 3.98 × 10
-3  
Table 6 
Estimated kinetic parameters and validation errors for the acetylation with different model structures (95% confidence intervals are in parenthesis).   
Model 1 Model 2 Model 3 Model 4 
Dataset batch Batch continuous batchþcontinuous 
Reaction 
schemes 
Eqs. (1.a, 1.b, 1.c) Eqs. (1.a, 1.c, 1.d) Eqs. (1.a, 1.c (irreversible), 1.d) Eqs. (1.a, 1.c, 1.d) 
A1  6.06 £ 105(3.77 × 104; 9.76 × 106) 4.34 £ 102(6.46 × 101; 2.91 × 103) 8.93 £ 103(1.23 × 103; 6.46 × 104) 7.48 £ 102(3.28 × 102; 1.71 × 103) 
Ea,1  56,313(49383; 63244) 38,802(34017; 43587) 48,138(42684; 53592) 40,172(38072; 42273) 
A2  1.93 (6.31 × 10-2; 5.59 × 101) 0 (fix) 0 (fix) 0 (fix) 
Ea,2  28,350(19283; 37417) 0 (fix) 0 (fix) 0 (fix) 
A3  3.54 £ 1016(6.06 × 1014; 2.07 ×
1017) 
2.83 £ 106(6.79 × 104; 1.18 × 108) 6.28 £ 106(3.94 × 10-2; 9.99 ×
1014) 
1.38 £ 108(3.60 × 10-9; 5.28 × 1024) 
Ea,3  124,397(112501; 136294) 62,468(52756; 72180) 74,964(20396; 129533) 70,497(-33965; 174960) 
Ar3  3.17 £ 10-14(6.74 × 103; 1.49 × 10-5) 4.70 £ 10-4(2.31 × 10-2; 9.58 × 10- 
6) 
0 (fix) 1.59 £ 103(8.72 × 10-2; 2.89 × 10-5) 
Ea,r3  0 (fix) 0 (fix) 0 (fix) 0 (fix) 
A4  0 (fix) 2.23 £ 104(2.34 × 103; 2.12 × 105) 2.53 £ 104(1.72 × 103; 3.71 × 105) 6.46 £ 104(5.02 × 103; 8.32 × 105) 
Ea,4  0 (fix) 53,862(48025; 59700) 56,114(49473; 62755) 56,601(49975; 63228) 
Errorb  1.36(0.63; 2.29) 0.79(0.41; 1.70) 0.86(0.17; 2.78) 1.02(0.48; 2.15) 
Errorc  95.0(73.7; 113.1) 35.4(19.3; 57.6) 46.8(11.8; 97.6) 42.5(23.2; 71.4)  
Table 4 
Constants and kinetic parameters of the crystallization model.  
Variable Unit Value 
kv  – π/6  
ρc  kgm− 3 1400 
Vc  m3 2.35 × 10-4 
kb  # m-3s− 1 3.48 × 106 
b  – 0.928 
kg  ms− 1 8.51 × 1011 
Ea,g  Jmol− 1 97,323  
Table 7 
Estimated kinetic parameters and validation errors for the quenching and 
dissolution models (95% confidence intervals are in parenthesis).  
Quenching Dissolution 
A5  1.44 £ 105(1.15 × 105; 1.82 
× 105) 
kd  1.98 £ 10-7(3.14 × 10-7; 1.25 
× 10-7) 
Ea,5  55,595 (fix) d  0 (fix) 
A6  0 (fix) p1  1 (fix) 
Ea,6  0 (fix) p2  0 (fix) 
A7  1.49 £ 107(9.19 × 106; 2.41 
× 107) 
Error  68.73 
Ea,7  84,153 (fix)   
A,r7  8.22 £ 101(8.27 × 100; 8.17 
× 102)   
Ea,r7  45,883 (fix)   
Error  1.90(1.57; 2.35)    
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the temporal evolution of the crystal’s population density function 
(n(L, t), denoting the number of crystals in the L,L+dL crystal size 
domain at t time) and the second term takes into account the effect of 
crystal growth. The right-hand side stands for the nucleation and the in- 











In Eqs. (22), L denotes the crystal size [m], t is the time [s], G is the 
rate of crystal growth [m s− 1], B is the rate of nucleation [#m− 3 s− 1], 
nin(L, t) is the number density function of crystals in the feeding stream 
[#m− 4], τc is the mean residence time in the crystallizer [s], Ln is the 
nuclei size [m] and δ is the Dirac-delta function. Ln has a very small, 
practically zero value, therefore it was neglected in the calculations. 
The initial condition (Eq. (23)) of the PBE gives the initial CSD n0(L)
in the crystallizer, whereas the boundary condition states that the 
crystals have a finite size (Eq. (24)). 
n(L, 0) = n0(L) (23)  
n(L→∞, t) = 0 (24) 
The secondary nucleation (Eq. (25)) is expressed as the function of 
the second moment of the distribution (μ2 [m2 m− 3], (Eq.(27)) and the 
relative supersaturation (σc) [-] (Eq.(27)). 








− 1 (27) 
In Eqs. (25)-(27), kb and b denote the nucleation rate coefficient [# 
m− 3 s− 1] and the nucleation rate exponent [-], respectively. c*c is the 
solubility [kg m− 3], which, in the case of a combined cooling-antisolvent 
crystallization, is dependent on the crystallization temperature (Tc [◦C]) 
and the antisolvent volume fraction v [-][30]: 
c*(Tc, v) = 54.51 − 118.1v+ 69.55v2 + 2.078Tc − 2.459vTc (28) 
The growth rate is described as a function of the relative supersat-
uration and a temperature-dependent rate factor (G0(σ,Tc)), as 
expressed in Eq. (29), where kg denotes the growth rate coefficient [m 
s− 1], Ea,g represents the activation energy of growth [J mol− 1]. 






Along with the PBE, the corresponding mass balances were solved for 





















where ρc [kg m− 3] and kv [-] represent the crystal density and 
volumetric shape factor, respectively. The mass balances have the c(0) =
c0 and v(0) = v0 initial conditions, which give the initial solute con-
centration and solvent composition in the crystallizer. 
A semi-discrete implementation of a high-resolution finite volume 
method (HR-FVM) was applied to solve the growth part (convective 
flux) of the PBE [34], simulating the CSD in the range of 0–2000 μm on a 
uniform grid with 500 cells. The constants used for the simulations are 
summarized in Table 4. For further details about the crystallization 
model development, the reader is referred to [30]. 
2.2.3. In vitro dissolution prediction 
The in vitro dissolution of the obtained ASA crystals was described 
using a population balance model. It could be assumed, that in the USP 
apparatus the temporal evolution of the n(L, t) population density 
function (i.e., the number-based CSD) is only affected by the dissolution 




∂L = 0 (32) 
where D is the rate of the dissolution [m s− 1] and the same initial and 
boundary conditions (Eq. (23–24)) apply as for the crystallization PBM. 
The calculation of the initial population density [# m− 4] from the 
normalized (measured or simulated) CSD is summarized in the 
Appendix. 
The size-dependent dissolution rate is defined as 
D(σd,L) = kdσdd(1 + p1L)
p2 (33) 
where kd and d denote the dissolution rate coefficient [m s− 1] and the 
dissolution rate exponent [-] and p1 and p2 are coefficients indicating the 
size-dependence of the dissolution. σd is the relative supersaturation, 
expressed in the same manner as for the crystallization model (Eq. (27)). 
Based on literature data [35,36], the solubility of ASA (c*d) in the 0.1 N 
HCl dissolution medium was approximated as 4 mg mL− 1, which was 
further converted to mass fractions. As the dissolution tests were con-
ducted by dissolving 100 mg ASA in the 900 mL dissolution medium (i. 
e., the maximum concentration is 0.11 mg mL− 1), this means, that 
experimentally the sink condition criteria met (i.e., dissolution media 
can dissolve at least 3 times the amount of drug that is the dosage form). 
Nevertheless, the supersaturation was accounted in Eq. (33) for the sake 
of better generalization of the model but is not expected to have a sig-
nificant effect in the studied case. As the dissolution tester maintains a 
constant dissolution temperature (Td) of 37 ◦C, the temperature 
dependence solubility is neglected. 
Along with the PBE, the mass balance for the solute concentration 






D(σd,L)L2n(L, t)dL (34) 
where cd denotes the ASA concentration in the dissolution medium. 





where mc, Vd and ρd correspond to the sample mass [kg], the volume 
of the dissolution medium [m3] and the density of the dissolution me-
dium [kg m− 3]. The values of these parameters were chosen based on the 
experimental method (see Section 2.1.3) and summarized in Table 5. DR 
[%] is the dissolved ratio, expressed as the percentage of the total 
sampled mass. Corresponding to the experiments, the dissolution was 
modeled for td,max = 120 min and during the integrated simulation the 
time (T85) needed to reach the 85% DR was also calculated. 
Similar to the crystallization model, a semi-discrete implementation 
of a high-resolution finite volume method (HR-FVM) was used for 
solving the PBE using the same computational grid. The parameter 
estimation was performed using the calibration powder samples sum-
marized in Table 3 and using the root mean square error (RMSE) be-
tween the measured and calculated concentration values as an objective 
function (O(kd, d, p1, p2)d). 














where DR,m,j and Kd denote the measured dissolved ratio and the total 
number of the sampled time points, respectively. 
For the sake of simplicity in the integrated simulation, it was 
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assumed, that the dissolution of the ASA capsules is mainly affected by 
the varying ASA particle sizes, that is the presence of the capsule shell 
causes a constant retarding effect. This assumption was also supported 
by the measured dissolution curves (see Section 3.1). Therefore, the 
model for the dissolution of the capsules was modified only by consid-
ering a linear relationship between the powder dissolution rate 
(D(σd, L)), that is multiplying D(σd, L) with a constant retarding factor. 
Once D(σd, L) was determined based on the powder dataset, the 
retarding factor was also estimated based on the experimental capsule 
dissolution curves (by minimizing the difference between the measured 
and simulated curves). Further, more detailed studies will be conducted 
in the future when the relationship between the powder and capsule 
dissolution is more complex, e.g., when considerable lag time also need 
to be accounted in the model due to the presence of the capsule shell, or 
the effect of excipients also need to be accounted. 
2.2.4. Integrated flowsheet model 
After developing the mathematical models of the unit operations as 
described in Section 2.2.1-2.2.3., the integrated process model was 
constructed as illustrated in Fig. 1. The properties of the reaction 
mixture were calculated by the synthesis model. The flow rate after 
quenching (Fq) is used for calculating the necessary flow rate of the 
antisolvent to obtain the defined antisolvent-solvent volume fraction (v). 
For simplicity, the antisolvent-solvent volume ratio (AS) is used further 





and consequently, the flow rate in the crystallizer is calculated: 
Fc = 76Fq + 76Fq⋅AS (38) 
As can be seen in Section 2.1, the synthesis and the crystallization 
experiments were conducted at a different scale, being the volume of the 
acetylation and quenching tube 4.19 and 0.89 mL, respectively, 
compared to the 235 mL MSMPR working volume. Therefore, Fq was 
multiplied by 76, which was found in preliminary studies to fit the 
experimental crystallization flow rates. Experimentally, this could mean 
that the synthesis is performed by using 76 parallel tubes. 
The ASA concentration in the quenched reaction mixture was used to 





(In the synthesis models, molar concentrations are calculated, 
whereas in the crystallization step these were converted into kg m− 3.) 
For the integrated simulations, the crystallization model was amended 
to also take into account the possible effect of the impurities (consid-
ering the sum of cq,A and cq,B) on the crystallization kinetics. It is 
important to note, that we have no experimental data about the impu-
rities influencing the crystallization, that is, this aspect of the study is 
purely for simulation purposes. However, the available literature sug-
gests, that for example, Impurity B (acetylsalicylic anhydride) may have 
an impact on the crystallization kinetics of ASA [37,38]. 
The crystal growth in the presence of the impurity was described 
using the model of Kubota and Mullin [39,40], where the impurities are 
assumed to be absorbed in kink sites with a pinning mechanism and with 
increasing surface coverage, this results in the linear decrease in the step 
velocity. By using the Langmuir adsorption isotherm, the step velocity 
can be related to the impurity concentration of the solution and with the 
assumption that the growth rate is proportional to the step velocity, the 
expression of the growth rate (Eq. (29)) is modified to 







where KL [kg m− 3] denote the Langmuir constant and α [-] is the 
effectiveness factor, that indicates how efficiently the impurity inhibits 
the crystal growth. When α > 1, the growth rate decreases fast to reach 
0 even at small KLci values, at α = 1 the growth rate approaches zero 
asymptotically, while for α < 1 it approaches a non-zero value. Although 
different impurity species can exhibit different effectiveness, for 
simplicity, in this study Impurity A and B were treated together. 
Consequently, the impurity concentration ci was expressed as: 
ci = cq,A + cq,B (41) 
As there were no experimental data available to estimate KL and α, 
different values were tested in sensitivity analysis to investigate their 
effect on the integrated model. 
The in vitro dissolution prediction model was connected downstream 
the integrated production of ASA with the assumption that appropriate 
filtration and drying occur between the crystallization and dissolution 
testing. These steps were studied by the authors of this paper [28,30]. It 
is also assumed that the moisture content of the ASA powder can be 
neglected after filtration and drying, that is the mass flow rate of the ASA 
powder (ṁ) can be directly calculated from the crystallization model: 
ṁ = Fc⋅cs (42) 
where cs denotes the solid concentration in the crystallization slurry. 
The dissolution model constantly performed the surrogate dissolution 
test with an mc sample mass every time a predefined mprod product mass 
is collected from the continuous line. The CSD of the sample is the 
average of the CSDs calculated by the crystallization during the 
Fig 1. Dynamic flowsheet model of continuous ASA production.  
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timeframe of the intermittent product collection. In this work, the value 
of mprod was set to 1000 mg, which means the dissolution testing after 10 
dosage units, however, it can be set to any arbitrary value e.g., to fit the 
sampling frequency requirements of the regulatory guidelines. 
2.3. Simulation case studies on the developed flowsheet model 
2.3.1. Optimization studies 
Optimization studies of the standalone synthesis, crystallization, as 
well of the integrated process were performed and compared. The 
optimization of the synthesis steps was conducted by calling the fmincon 
optimization function of Matlab® with the default interior-point algo-
rithm. The integrated flowsheet model was optimized in the Simulink 
Design Optimization Toolbox, where the sequential quadratic pro-
gramming algorithm was used. 
For the synthesis, five process parameters were chosen to be opti-
mized: the temperature of the acetylation (Ta) and quenching reactor 
(Tq), the amount of AA (AAeq) and EtOH (EtOHeq) expressed as the mole 
equivalent of the initial SA and the residence time in the acetylation 
reactor (τa), which, together with AAeq and EtOHeq, determines the 
residence time in the quenching reactor, too. Additionally, the 
constraint of EtOHeq ≥ AAeq was used to ensure that the quenching 
reactor can result in the total decomposition of AA. The synthesis opti-
mization aimed to obtain the highest conversion (X) at the end of the 
operation (as the objective function, -X was minimized): 
X[%] =
cASA + cA + cB
c0a,SA
⋅100 (43) 
Additionally, the purity (P) of the obtained reaction mixture was also 
calculated as Eq. (44). 
P[%] =
cASA
cASA + cA + cB + cSA
⋅100 (44) 
When the crystallization and the integrated continuous 
manufacturing line was studied, the crystallization operation parame-
ters of Tc and AS were also included as decision variables. In this case, 
the overall productivity [g h− 1], the mean particle size (D[1,0], i.e., the 
arithmetic number mean of the CSD), and the dissolution properties 
(T85, i.e., the dissolution time necessary for the dissolution of the 85% of 
the API) were the objectives with equal weight. As τa, AAeq, EtOHeq and 
AS are optimized, and the crystallizer is assumed to be operated in a 
constant volume, the residence times in the quenching reactor (τq) and 
the in the crystallizer (τc) are also defined by these parameters, that is 
remained no freedom to independently vary τc during the optimization. 
Nevertheless, one could vary the slurry level in the crystallizer to 
manipulate the mean residence time, but due to technical limitations 
(including the stirring effectiveness), this range is limited, therefore, in 
this work, it was decided to fix the crystallizer volume. Consequently, for 
comparability with the integrated process, even in the stepwise opti-
mization case, τc was not handled as a decision variable. 
2.3.2. Sensitivity analysis 
Two separate sensitivity analysis studies were conducted to analyze 
the effect of uncertainty of the operational parameters (the parameters 
used in the optimization studies) as well as the kinetic parameters on the 
CQAs. For the latter, 11 parameters were used: the k1, k3, k4, k5, k7 and 
k7r reaction rate constants, kb, kg, KL and α of the crystallization model 
and kd for the dissolution process. 
For screening and ranking the importance of the parameters, the 
Morris method, also called the elementary effect test [8,41], was used, 
which is a multiple-start, global perturbation method. Perturbation 
methods vary (perturb) the input factors (x1,…xi,…,xN) one-at-a-time 
(OAT) from the nominal value and quantify their effect on the g scalar 
output by calculating the partial derivatives. As the analytical form of 
the input–output relationship is rarely known, this is approximated by 












where (x1,⋯, xi +Δi,⋯, xN) denote the ith perturbation and ci is a 
scaling factor to facilitate the comparison of the input factors having 
different units. In the Morris method, this finite difference is called the 
elementary effect (EE). To make the method global, i.e., to consider the 
variation within the entire variability space of the input parameters, r 
EEs are computed within the input space, and the mean (μM) and stan-
















To assess the sensitivity of the output to the inputs, μM and σ2M are 
analyzed in parallel. A high μM value indicates the high influence of the 
given input factor and a high σ2M means that the sensitivity changes 
across the variability space, which can be either caused by a non-linear 
effect or because of the interaction with the other factors. In this work, 
the productivity, D[1,0], T85, the impurity and ASA concentration after 
quenching and the solid concentration of crystallization were used as g 
outputs. 
Several strategies exist for the selection of the xi sampling points and 
Δi variations, which are discussed in detail elsewhere [8]. In this work, 
the radial design OAT sampling strategy [42] was used where the Δi 
variations were taken from the same xi points, selected based on a Latin 
Hypercube. 
As the calculation of one EE (Eq. (45)) requires (N + 1) model 
evaluations, a total of r(N+1) simulations are required for performing 
the Morris analysis, which is computationally cheap compared to other, 
e.g., variance-based global sensitivity analyses. As a rule of thumb, the 
number of r is usually advised to be around 10-100N to reach conver-
gence and obtain the indices with satisfactory confidence intervals for 
ranking. This was reached using 125 EEs in the analysis of the opera-
tional parameters (meaning a total of 1000 model evaluations), whereas 
the sensitivity of the kinetic parameters was studied using 40 EEs (480 
total simulations). All the calculations related to the sensitivity analysis 
(sampling, calculation of Morris indices, confidence intervals, and the 
analysis of convergence) were performed using the SAFE toolbox 
[43,44]. 
3. Results and discussion 
3.1. Parameter estimation results 
The parameter estimations were performed using different combi-
nations of the possible kinetics (e.g., accounting or neglecting the 
reversibility of a reaction) and reaction schemes (e.g., considering the 
different possible reactions (Eq. 1.a-1.d) during acetylation) to find the 
best fit to the experimental results. In the case of the acetylation process, 
the models also used different experimental data. 
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Table 6 summarizes the considered kinetic models for acetylation 
and the obtained errors for the batch (Errorb) and continuous (Errorc) 
validation samples. These errors were calculated the same way as 
O(D)batch and O(D)cont during the parameter estimation (see Eq. (20, 
21)), with the exception that for the continuous validation data, w = 0 
was applied in Eq. (21), that is the nMSE values of the ASA, SA and 
impurity concentration predictions were summarized. Comparing Model 
1 and 2, it is apparent that both models utilize only the batch calibration 
data, however Errorb and Errorc were significantly lower than in Model 2. 
This was caused by the difference in accounting the formation of Im-
purity A: while Model 1 assumed that the formed ASA takes part in 
subsequent acetylation (Eq. (1.b)), it was found that the simulations fit 
better the experimental data when Impurity A is assumed to be produced 
by the double acetylation of SA with the excess AA (Eq. (1.d)). There-
fore, in further investigations only the latter route was accounted. 
Utilizing the batch or continuous calibration data did not result in 
such considerable changes in the validation error values and the most 
substantial difference occurred in the confidence intervals. Fig. 2 illus-
trates the fit of prediction with Model 2–4 to the experiment of Abatch Val 
2. The same conclusions could be drawn from the other two validation 
experiments. Although Fig. 2 suggests a relatively simple polynomial 
form as the dynamics, it needs to be accounted that for the model fitting, 
10 parameters (see Table 6) needed to be simultaneously estimated, 
using the ordinary differential equation systems detailed in Section 2.2.1 
and Appendix A.1, while relatively small experimental dataset was 
available for fitting. This is the reason for the wider confidence intervals 
(also seen in Figs. 3 and 4), and given these limitations, the model fit 
could be deemed to be satisfactory to estimate the dynamics of the 
process. It also needs to be noted, that the concentration of Impurity B is 
one order of magnitude smaller than that of the other parameters, 
therefore the seemingly big difference between the measured and pre-
dicted concentrations in Fig. 2. Although at Model 3, the parameter 
estimation was performed using only steady-state concentration data, it 
is apparent, that it could also describe the dynamics of the batch process 
with comparable accuracy as Model 2. However, the wider confidence 
intervals indicate a higher uncertainty of the parameters, which could be 
explained by the smaller continuous dataset used for the estimations i.e., 
only steady-state concentrations were available. This also appeared in 
continuous validation results (Fig. 3). Model 4, where continuous and 
batch data were used combined, provided similar results to Model 2 for 
Fig 2. Predicted and measured concentration for Abatch Val 2 setting with a) Model 2, b) Model 3, c) Model 4.  
Fig 3. Predicted and measured concentrations for the continuous validation acetylation settings with Models 2 and 3.  
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both the batch and continuous validation results, with slightly different 
confidence intervals, therefore Model 4 is not depicted in Fig. 3. The SA 
concentrations of the continuous validation experiments were over-
estimated with Model 3, while higher inaccuracies in the ASA content 
were observed with Model 2. However, the trends between the different 
experimental settings were followed better with Model 3, therefore, the 
kinetic parameters of Model 3 were used in the integrated flowsheet 
model. In Fig. 3, the effect of the decreasing temperature and the 
simultaneous increase of the residence time (see Table 1) can be fol-
lowed: from Acont Val 1 to 3 the ASA and SA concentrations were 
increased slightly, while the amount of the impurities decreased. The 
analysis of the effect of the operating conditions on the concentrations is 
detailed in Section 3.3. 
Several combinations of the kinetic parameters and reaction schemes 
were also tested for the quenching step of the synthesis, however, there 
were no substantial differences observed in the quality of the fit, 
therefore in Table 7, only the final parameters are summarized. The 
validation error was calculated the same way as explained in the case of 
acetylation. It is notable that A6 and Ea,6 are fixed to 0, which is 
explained by the fact that there was no available experimental data 
about the concentration of the EtOAc, HA and EtOH after quenching. 
However, in preliminary parameter estimation calculations the value of 
k6did not influence the concentration of the other components. There-
fore, with the assumption that the total decomposition of AA completes 
fast in the quenching reactor, this reaction was neglected. Furthermore, 
having only the limited dataset of continuous steady-state measure-
ments, the activation energies were fixed to values found adequate 
during the preliminary studies to decrease the uncertainty of the 
parameter estimation. Fig. 4 shows that the quenching model could 
predict the concentration variations caused by the different operations 
of the quenching reactor. The temperature and the residence time in the 
quenching reactor and the EtOH amount were varied simultaneously in 
the validation experiments (see Table 2). It is visible that in the case of Q 
Val 5–6, the SA concentration could be determined with higher uncer-
tainty, which is associated with the longer residence times. However, the 
variability of the calculated ASA concentration was lower than that of 
the experimental values, which indicates that effects associated with the 
changes in ASA concentration might be underestimated when the model 
is utilized in the flowsheet simulation. As the trends depicted in Fig. 4 
show the simultaneous variation of the three operational parameters, 
the analysis of these effects is complicated, but it is further addressed in 
the sensitivity studies (Section 3.3). 
Although some of the kinetic parameters for the acetylation and 
quenching step could be estimated only with wide confidence intervals, 
which suggest that the parameters are correlated and the resulting un-
certainty space is relatively large, yet the nominal values of the pa-
rameters were found to provide a satisfactorily good agreement with the 
experimental results. This shows that by using the nominal parameters, 
the models can be used for further analysis of the operational parame-
ters’ effect. Also, based on these parameter estimation results, one could 
carry out a robust optimization, which directly involves the parameter 
uncertainties. To further address the question of the effect of the 
parameter uncertainty, the kinetic parameters were also studied by 
sensitivity analysis (see Section 3.3), to revealed which parameters are 
critical. In future work, the confidence interval of these parameters 
could be reduced by utilizing more experimental data for the parameter 
estimation. 
The parameter estimation of the dissolution model resulted in the 
substantial simplification of the dissolution rate expression (Eq. (33)) 
because it was found that the p1 and p2 take extremely uncertain values 
as well their value did not influence the accuracy of the prediction. This 
resulted in the simplification of the size-dependent term into size- 
independent dissolution expression. Although it is well known that the 
smaller particles dissolve faster, these effects are significant at nano-
scale, but the size dependency of the solubility vanishes over a few 
micrometers. In this study, the initial particles exposed to dissolution 
were generally well over this size range and the majority of the solids are 
already dissolved when the particles shrink to this size. Therefore, the 
simulated concentration curve remains valid in the solute concentration 
variation domain of interest and this explains the adequacy of the size- 
independent dissolution rate. Regarding d and kd, since a low amount of 
solid was dissolved relative to the solvent volume and the experiments 
were performed under sink conditions, meaning that the change in the 
supersaturation is not relevant, it was impossible to decouple d from kd 
and therefore d was fixed to 1. The final kinetic model (see Table 7) 
including only the dissolution rate coefficient was suitable for the sur-
rogate modeling of the dissolution curve of the validation samples 
(Fig. 5). 
As for the dissolution of the ASA filled into capsules, the experi-
mental capsule dissolution curves (green lines in Fig. 5) exhibit a slower 
release compared to the powder measurements, but no lag time was 
observed due to the dissolution of the capsule shell, as it started to 
dissolve within the first two minutes of the test. Therefore, the 
assumption of the constant retarding effect was found to be adequate for 
this case, and the multiplication of the dissolution rate (D(σd, L)) by the 
constant retarding factor of 0.5 was found to provide a reasonably good 
fit as seen in Fig. 5. This approach is admittedly a significant simplifi-
cation, which is not suitable for several capsule formulations e.g., due to 
the possible API-excipient interactions or a potential lag time caused by 
the slow dissolution of the capsule shell, in which cases further model 
development would be necessary. However, such a simplified method 
could contribute to a better understanding of the effect of the crystal size 
distribution as CMA and the corresponding optimization and risk anal-
ysis of the manufacturing process of the API during the early stage of the 
drug development. 
Fig 4. Predicted and measured concentration for the quenching validation experiments.  
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3.2. Optimization of the integrated continuous line 
To investigate how the integrated flowsheet simulation can 
contribute to better understanding and operation of the continuous 
manufacturing line, several optimization problems were defined and 
solved. First, the standalone synthesis was considered, followed by the 
examination of the integrated synthesis and crystallization processes. 
The goal of this comparison is to compare the achievable product quality 
attributes if all operations are optimized individually subject to local 
objectives vs. the plant-wide optimization of the integrated process using 
the developed flowsheet model. In the former approach the operating 
parameters of the synthesis were optimized in three stages: in the first 
stage the optimal value of AAeq was determined using batch acetylation, 
along with an optimal batch Ta. In the next stage, the flow acetylation 
process parameters (τa and Ta for the continuous reactor) were opti-
mized while AAeq was fixed for the value found optimal in the batch 
acetylation. In the last step, the quenching parameters (Tq and EtOHeq) 
were optimized with the fixed acetylation process. Compared to this, in 
the second approach, all parameters could be simultaneously optimized. 
The optimization results are summarized in Table 8. 
While the 3-stage procedure is identical to the experimental opti-
mization procedure [28] and is a common practice to reduce the 
necessary number of experiments, the simulation results clearly showed 
the advantages of considering the reactor cascade in the optimizations. 
Table 8 shows that the integrated process optimization resulted in 10% 
higher conversion compared to the step-by-step procedure. Moreover, 
this was achieved along with the significant increase in the purity of the 
reaction mixture, too, which can further simplify the purification (e.g., 
crystallization) steps. The most substantial difference in the operation 
parameters of the two approaches could be found in the applied AA and 
EtOH excess. It is apparent, that in the batch acetylation stage of the 
step-by-step approach, the optimal value of AAeq was fixed to the upper 
boundary along with a relatively low temperature, as the excess AA 
promotes the conversion of SA in the acetylation step, which also 
resulted in high necessary EtOHeq in the quenching step. However, as the 
integration optimization indicated, it was beneficial from the point of 
the global conversion to process an acetylated reaction mixture with 
lower conversion (87.4% as opposed to 93.5% of the step-by-step 
method) than aiming for maximal conversion at each stage. The lower 
amount of AA and EtOH could be compensated with higher tempera-
tures and longer residence time. At this stage of the work, the integrated 
results have not been directly experimentally validated, yet. However, 
as the models of all the unit operation are individually validated and the 
acetylation and the quenching model steps were directly integrated 
without further assumptions (i.e., all the obtained component 
concentrations after acetylation were used in the quenching model), it 
can be expected that the integrated calculation does not influence the 
validity of the results. Also, the comparison of the stepwise optimization 
simulations with the experiments (see [28]) showed good agreement, e. 
g., the experimental batch acetylation optimization suggested high AAeq 
value, but it also promoted the formation of the impurities, whereas the 
increase of the temperature and residence time increased the purity in 
the flow acetylation. 
The integrated continuous synthesis- crystallization process was 
optimized to provide the highest productivity [g h− 1]. This was also 
done in different ways: first, the synthesis process was fixed to the “Stage 
3” and “Integrated synthesis” conditions from Table 8 and the crystal-
lization process parameters (Tc and AS) were optimized, then the entire 
reaction-crystallization cascade was optimized in an integrated way. In 
the first case, the synthesis settings of both the previous step-by-step 
(Fixed synthesis 1 in Table 9) and integrated approach (Fixed synthesis 
2 in Table 9) were tested to examine whether optimized crystallization 
Table 8 
Optimization results of the synthesis step with the step-by-step and integrated 
approach. The allowed parameter ranges are given in parenthesis next to the 











AAeq[-](1–10)   9.99 9.99 (fix) 9.99 (fix)  1.22 
Ta(batch) 
[◦C](0–100)   
28.01 – –  – 
Ta(cont.) [◦C] 
(0–150)   
– 80.22 80.22 (fix)  150.00 
τa[min] 
(60–300)   
– 82.65 82.65 (fix)  100.14 
Tq[◦C] 
(0–150)   
– – 40.06  78.81 
EtOHeq[-] 
(1–15)   













– – 72.5  82.8 
Final purity 
[%]  
– – 60.4  87.6  
Fig 5. Predicted and measured validation experiments for the validation dissolution samples.  
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could compensate for the different conversion in the reaction mixtures. 
As seen in Table 9, to obtain high productivity, high antisolvent-solvent 
volume ratios are suggested, while the relatively high crystallization 
temperatures could be associated with the high activation energy of the 
crystal growth [30]. It is noticeable, that the optimized crystallization 
settings for both Fixed synthesis 1 and 2 resulted in similar values, yet the 
higher conversion rate in the synthesis provided a doubled productivity 
of the final ASA product. This suggests that even the optimization of the 
multi-step synthesis as a unit can result in a vast improvement in the 
overall performance of continuous manufacturing. Nevertheless, when 
the synthesis-crystallization process was studied in an integrated way, 
the productivity could be further increased to 40.6 g h− 1, which was 
mainly associated with the decrease of the residence time. The calcu-
lated synthesis conversion value was between the settings of the two 
previously studied syntheses, which further emphasizes that the stand-
alone optimization of the synthesis, without the crystallization step, is 
not sufficient to reach maximum productivity at the end of the contin-
uous line. 
In summary, the integrated plant-wide optimization resulted in a 3.2- 
fold overall productivity improvement compared to the optimization of 
individual units, which clearly demonstrates the benefit of the devel-
opment of flowsheet simulations. Furthermore, these results were 
reached with lower excess of AA and EtOH, that is not only the pro-
ductivity is increased, but the material costs and environmental foot-
prints are also reduced. The conclusions drawn from these optimizations 
could contribute to the experimental integration of the unit operation 
with fewer but more targeted experiments. Therefore, future studies will 
aim the experimental realization of the above results, which could also 
validate the integrated flowsheet model. 
As most of the pharmaceutical manufacturing processes are not 
solely aims to maximize the productivity, but also to achieve pre-defined 
properties of the final product, a multi-objective optimization was also 
performed using the integrated flowsheet model. In this case, besides the 
maximization of the productivity, the mean particle (D[1,0]) was also 
aimed to be maximized, as this significantly influences the downstream 
processability, such as the filtration [30] or blending. However, as the 
particle size also affects the dissolution properties, the additional 
constrain of the dissolution of the ASA capsules was also added. This was 
defined such as the T85, i.e., the dissolution time necessary for the 
dissolution of the 85% of the API, must be equal to or<15 min in 0.1 N 
HCl. This criterium ensures for high solubility, high permeability (BCS I) 
drugs, like ASA, that the bioavailability is not limited by the dissolution, 
therefore it can be regarded as an immediate-release formulation [45]. 
As the results in Table 9 shows, this was achieved by the reduction of Tc 
and Tq and the applied EtOH amount was also increased. While the 
additional objective and constraint reduced the productivity to 30.5 g 
h− 1, this could be still regarded as relatively good productivity and 
represents a good trade-off for product quality. However, to fulfill the 
dissolution criteria, the particle size had to be significantly reduced 
compared to the previous results. The 41.6 μm D[1,0] value can be 
associated with good filterability [30], but flowability problems might 
occur which may need to be addressed. 
3.3. Sensitivity analysis 
Sensitivity analyses were conducted at the operation point of the 
process at the settings obtained by the multi-objective optimization (last 
column in Table 9). The identification of the effects and risks associated 
with the involuntary changes in the process parameters and the uncer-
tainty in the kinetic parameters of the simulation was the objective. This 
way, the flowsheet modeling can help to understand the development 
and operation of the integrated continuous manufacturing lines better 
and it also contributes to the determination of PAT and control 
strategies. 
To study the sensitivity of the operational parameters, first, the input 
variability space had to be defined. This can be performed based on 
experimentally observed uncertainty and process characteristic. It was 
assumed that the uncertainty of the operating parameters occurs due to 
the random disturbances, which are handled as normally distributed 
random variables. The standard deviations (STDs) of the distributions 
were first defined as the 20% of the mean for each parameter, then in a 
second run it was refined such as the STDs of AAeq, AS, EtOHeq and τa 
were 10% of the mean values, but 5, 5 and 20% forTa, Tq and Tc, 
respectively. This was determined based on the experimental observa-
tions that Ta and Tq can be kept at the required value very well, but Tc 
showed high uncertainty during the processes. The two runs did not 
show significant differences, therefore only the results of the second are 
presented here in detail. 
The simulated parameter space is illustrated in Fig. 6 with the color 
scale indicating the steady-state productivity values. The dynamic re-
sponses of the simulations can be seen in Fig. 7, which can help analyze 
the error propagation through the system. It is noticeable that the un-
certainty of the input space significantly affects the output variability 
considering either the productivity, the crystallization slurry properties, 
or the reaction mixture concentrations. With 95% confidence, the pro-
ductivity was found to be varying between 16.0 and 39.3 g h− 1, how-
ever, some extreme parameter combinations exhibited strong 
detrimental effect resulting in productivity below 10 g h− 1. The D[1,0] 
and T85 values were found to be varying between 26.6 and 64.4 and 
10.4–20.0 min, respectively, the latter meaning, that the risk of failing 
the immediate-release specification is very high. The cumulative dis-
tribution functions (CDFs) of the parameters belonging to the 
immediate-release and the out-of-specification T85 values (Fig. 6) 
showed no difference for any of the parameters but the Tc, where two 
distinct CFDs were observed: the one belonging to the immediate-release 
capsules ranging from 0 to 23 ◦C, while the out-of-specification setting 
starting at 23 ◦C. This highlights that keeping Tc under 23 ◦C is vital for 
obtaining the required quality of the capsules, which must be addressed 
Table 9 
Optimization results of the integrated process. The allowed parameter ranges are given in parenthesis next to the parameter names.   
Fixed synthesis 1 Fixed synthesis 2 Integrated synthesis þ crystallization Multi-objective optimization 
AAeq[-] (1–10)  9.99 (fix) 1.22 (fix) 1.00 1.00 
Ta(cont.) [◦C] (0–150)  80.22 (fix) 150.00 (fix) 150.00 150.00 
τa[min] (60–300)  82.65 (fix) 100.14 (fix) 60.00 60.00 
Tq[◦C] (0–150)  40.06 (fix) 78.81 (fix) 76.69 57.57 
EtOHeq[-] (1–15)  10.00 (fix) 1.22 (fix) 1.00 5.21 
Tc[◦C] (0–50)  40.66 42.30 39.52 21.55 
AS[-] (1–8)  8 7.70 8 8 
Conversion after synthesis [%] 72.5 82.8 77.0 63.5 
Purity after synthesis [%] 60.4 87.6 80.2 79.4 
Overall productivity [gh¡1] 12.6 24.6 40.6 30.5 
D[1,0] [μm] 86.4 91.9 84.8 41.6 
T85 [min] 27.9 29.7 27.4 14.0  
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when developing the control strategy. 
As for disturbance propagation, it is visible from Fig. 7, that the 
productivity and the mean particle size change immediately (within a 
few minutes) after the change of the parameter from the steady state of 
the nominal operational parameter. However, 8 min lag-time was 
observed at the change of the dissolution property, followed by a slower, 
gradual transition lasting about 30 min. The variation in the concen-
trations of the final reaction mixture was also studied, which also 
revealed an approximately 5 min lag-time with a long transition time, 
which could be associated with long residence time in the flow reactors. 
Fig 7. Output uncertainty along the simulation time. The solid and dashed black lines represent the mean and the 95% confidence interval of the 1000 model 
evaluations, respectively. 
Fig 6. The simulated input parameter space (1000 model evaluations) and the cumulative distribution functions of the simulations belonging to the immediate- 
release and out-of-specification dissolutions. The color of the dots represents the productivity obtained with the given parameters. The readers are referred to the 
on-line version of this paper for the colored figure. 
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The Morris indices calculated for each simulation time point helped 
understand these observations better (Fig. 8). Starting with the mean 
particle size, the greatest μM and σ2M values were obtained for Tc, 
whereas the indices of other parameters were insignificant. As the 
dissolution properties of the final capsules are calculated based on the 
CSD, it was expected, that for the T85, Tc also emerged as the most 
influential parameter. However, in the first hour of the simulation, the 
relatively high σ2M of τa and AS indicate their non-linear effect or inter-
action with other parameters, which can be the explanation of the 
slower transition to the new T85 value. Moving on to the concentrations 
of ASA and impurity in the reaction mixture, the three operating pa-
rameters of the acetylation step were identified as significant, among 
which AAeq resulted in the highest μM and σ2M. The dynamic represen-
tation also allows noticing that during the transitional state, the non- 
linear effect or interactions associated with AAeq and τa changes non- 
monotonically, which might be caused by the multiple, concurrent re-
actions influencing the concentrations. The most complex outcome of 
the sensitivity analysis was discovered for the overall productivity. 
While Tc appeared again as the most influential parameter, the AS and τa 
also exerted an immediate effect. It needs to be noted that the high 
impact of Tc was not only resulted due to its defined higher uncertainty, 
but the same importance was observed when the STDs of all parameters 
were defined equal. AAeq showed comparable results as AS, however, its 
effect evolves gradually in 120 min. These results further reinforce the 
observations of the optimization study, too, i.e., it is critical to control 
the whole integrated process as a system, to ensure consistent and 
satisfactory productivity. Another important conclusion of the sensi-
tivity analysis, that the parameters of the quenching unit (EtOHeq,Tq) 
were not found significant for any of the analyzed objectives, which 
suggests that this might be the most robust unit and its control is less 
vital than that of the acetylation and crystallization. 
With the sensitivity analysis of the kinetic parameters, the question 
of the uncertainty of the developed model was addressed. Although the 
confidence intervals of the kinetic parameters indicate the parameter 
uncertainty, it was too wide to be further used in the sensitivity analysis, 
as it resulted in several computationally infeasible parameter combi-
nations. Therefore, the uncertainty of all parameters was defined as 
normal distributions, the mean being the estimated parameter (see Ta-
bles 4, 6 and 7) and using the 5% of the mean value as the STD. The 
results of the Morris screening are illustrated in Fig. 9 for the steady state 
of the productivity, mean particle size and dissolution property. The 
productivity was found to be influenced by α, i.e., the effectiveness 
factor of the impurities, as well as by k1 and k4, that is the reactions 
when SA is converted into ASA and Impurity A. The D[1,0] was found to 
be mainly affected by α, kd and the crystallization kinetics (kb, kg) had a 
significant effect on the dissolution of the ASA capsules. 
The results of the sensitivity analysis of the operating parameters and 
the kinetics parameters support each other as the importance of the 
crystallization is clearly revealed in both cases as well as the produc-
tivity is found to be influenced by both the acetylation and crystalliza-
tion steps, while the uncertainty in the quenching kinetics was found to 
be less important. The most noticeable is the great impact of α, which is a 
clear indication that whenever crystal growth rate inhibition by a re-
action byproduct appears, this needs to be treated with extra care. 
Interestingly, although the Kubota model is governed by both the α and 
the Langmuir constant (KL), the value of KL was found to be insignificant 
in the Morris analysis. Therefore, to improve the reliability of the 
flowsheet model, further studies need to focus mainly on the estimation 
of α. 
Fig 9. Morris sensitivity indices of the kinetic parameters in the steady state of the simulations.  
Fig 8. Time-varying Morris sensitivity indices. The dotted lines represent the 95% confidence interval of the indices.  
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4. Conclusions 
In this work, the dynamic flowsheet model was developed for the 
integrated, continuous manufacturing of ASA based on the experimental 
data of continuous unit operations to facilitate the integration. Together 
with our previous work on the modeling of continuous filtration [30], 
the dynamic model of the fully integrated, continuous upstream 
manufacturing was achieved. The optimization of the integrated process 
resulted in a significant overall productivity increase compared to the 
step-by-step optimization of the unit operations, and at the same time, 
the excess of the reactants could be decreased, which highlights the 
impact of the flowsheet modeling on the economic and environmental- 
friendly operation of the manufacturing. 
Furthermore, the surrogate model of the in vitro dissolution test of 
ASA capsules was integrated into the flowsheet model the first time, 
which enabled the risk analysis of the failure of the dissolution specifi-
cations of an immediate-release formulation. The presented dissolution 
model is directly applicable for capsule formulations where the excipi-
ents, e.g., fillers or diluents do not influence the dissolution rate and 
hence the only critical factor is the CSD, but it might be also useful in the 
case of more complex formulations to analyze the effect of the CMAs 
individually and optimize the manufacturing accordingly. Future work 
will also address the modeling of further formulations (e.g., tablets) and 
their integration into flowsheet models when multiple critical material 
attributes and process parameters need to be accounted. The calculation 
of the time-varying sensitivity indices helped understand the most 
influential operational parameters and the risks of error propagation. 
Although the presented dissolution model was developed for a fairly 
simple formulation (i.e., capsules, where the CSD of the API determined 
the dissolution property), the presented work indicates its importance, 
and hence it could encourage further studies to incorporate the disso-
lution model of the final formulations (e.g., tablets), using either 
mechanistic or black-box modeling approaches. This work also high-
lighted the high impact of crystal growth inhibition on the final product 
properties. 
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Appendix 
A.1 Reaction network 
The reaction rate equations were expressed as 
r1 = k1⋅cSA(t)⋅cAA(t) (A1.a)  
r2 = k2⋅cASA(t)⋅cAA(t) (A1.b)  
r3 = k3⋅cA(t)⋅cASA(t) (A1.c)  
r3r = k3r⋅cB(t)⋅cHA(t) (A1.d)  
r4 = k4⋅cSA(t)⋅c2AA(t) (A1.e)  
r5 = k5⋅cA(t)⋅cEtOH(t) (A1.f)  
r6 = k6⋅cAA(t)⋅cEtOH(t) (A1.g)  
r7 = k7⋅cASA(t)⋅cEtOH(t) (A1.h)  
r7r = k7r⋅cSA(t)⋅cEtOAc(t) (A1.i) 
where cX denotes the concentration of the given reagent. 
With these, the ODE system of the acetylation step can be written as: 
dca,SA
dt
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The ODE system describing the quenching step: 
dcq,SA
dt














































A.2 Determination of initial CSD for the dissolution model 
The initial CSD (n0(L)) for the dissolution PBM was calculated from the normalized measured CSDs (see Section 2.1.3) or the CSDs simulated using 





where nm(L) is the normalized CSD of the sample to be dissolved (either the measured CSD of the samples detailed in Section 2.1.3 or the CSD 













where mc, Vd and ρd correspond to the sample mass [kg], the volume of the dissolution medium [m3] and the density of the dissolution medium [kg 
m− 3]. The values of these parameters were set following the experimental method (see Section 2.1.3) and summarized in Table 5. 
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